Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

• Status: Recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory learning.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Diego
• Treatments: Memantine

Criteria

Inclusion Criteria:

• diagnosis of schizophrenia OR schizoaffective-depressed OR healthy subjects

• ages 18-50 for all subjects

• double barrier contraception for all subjects

• not pregnant for all subjects

Exclusion Criteria:

• DSM-IV Axis I or II Diagnosis for for healthy subjects

• MEM or amantadine for patients

• current substance abuse for all subjects

• current recreational drug use for all subjects

• history of other significant medical illness (e.g. cancer, diabetes, heart disease, HIV, seizures) for all subjects

• open head injury or closed head injury with loss of consciousness > 1 min for all subjects

• hearing or visual impairment for all subjects

• pregnancy for all subjects

• dementia for all subjects

• mental retardation for all subjects